{"id":32493,"date":"2025-04-27T16:43:41","date_gmt":"2025-04-27T08:43:41","guid":{"rendered":"https:\/\/flcube.com\/?p=32493"},"modified":"2025-04-27T16:43:42","modified_gmt":"2025-04-27T08:43:42","slug":"ltz-therapeutics-secures-40m-series-a-to-advance-immunotherapy-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32493","title":{"rendered":"LTZ Therapeutics Secures $40M Series A+ to Advance Immunotherapy Pipeline"},"content":{"rendered":"\n

Shenzhen-based LTZ Therapeutics has reportedly raised USD 40 million in a Series A+ financing round led by Wanwu Growth Venture Capital. The round also saw participation from Lanchi Ventures, 5Y Capital, Unicorn Capital Partners, the Institute for Follicular Lymphoma Innovation, and returning investors Lapam Capital and GL Ventures. The proceeds will be used to advance the Phase I clinical trial of its first drug candidate, LTZ-301, and to submit an Investigational New Drug (IND) application for its second candidate, LTZ-232, targeting pan-tumor indications.<\/p>\n\n\n\n

Company Background and Technology<\/strong>
LTZ Therapeutics, founded in 2022, is focused on addressing unmet clinical needs in cancer and autoimmune diseases. The company is developing novel immunotherapies based on its proprietary \u201cmyeloid cell adapter\u201d technology platform. These therapies aim to enhance the phagocytic function of macrophages and monocytes across different polarization states, offering broad-spectrum immunotherapy solutions. Since its inception, LTZ Therapeutics has raised a total of USD 90 million.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Shenzhen-based LTZ Therapeutics has reportedly raised USD 40 million in a Series A+ financing round…<\/p>\n","protected":false},"author":1,"featured_media":32494,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,20,458],"class_list":["post-32493","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-biotech","tag-finance","tag-ltz-therapeutics"],"yoast_head":"\nLTZ Therapeutics Secures $40M Series A+ to Advance Immunotherapy Pipeline - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shenzhen-based LTZ Therapeutics has reportedly raised USD 40 million in a Series A+ financing round led by Wanwu Growth Venture Capital. The round also saw participation from Lanchi Ventures, 5Y Capital, Unicorn Capital Partners, the Institute for Follicular Lymphoma Innovation, and returning investors Lapam Capital and GL Ventures. The proceeds will be used to advance the Phase I clinical trial of its first drug candidate, LTZ-301, and to submit an Investigational New Drug (IND) application for its second candidate, LTZ-232, targeting pan-tumor indications.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32493\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LTZ Therapeutics Secures $40M Series A+ to Advance Immunotherapy Pipeline\" \/>\n<meta property=\"og:description\" content=\"Shenzhen-based LTZ Therapeutics has reportedly raised USD 40 million in a Series A+ financing round led by Wanwu Growth Venture Capital. The round also saw participation from Lanchi Ventures, 5Y Capital, Unicorn Capital Partners, the Institute for Follicular Lymphoma Innovation, and returning investors Lapam Capital and GL Ventures. The proceeds will be used to advance the Phase I clinical trial of its first drug candidate, LTZ-301, and to submit an Investigational New Drug (IND) application for its second candidate, LTZ-232, targeting pan-tumor indications.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32493\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-27T08:43:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-27T08:43:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2705.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32493#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32493\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"LTZ Therapeutics Secures $40M Series A+ to Advance Immunotherapy Pipeline\",\"datePublished\":\"2025-04-27T08:43:41+00:00\",\"dateModified\":\"2025-04-27T08:43:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32493\"},\"wordCount\":163,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32493#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2705.webp\",\"keywords\":[\"Biotech\",\"Finance\",\"LTZ Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32493#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32493\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32493\",\"name\":\"LTZ Therapeutics Secures $40M Series A+ to Advance Immunotherapy Pipeline - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32493#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32493#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2705.webp\",\"datePublished\":\"2025-04-27T08:43:41+00:00\",\"dateModified\":\"2025-04-27T08:43:42+00:00\",\"description\":\"Shenzhen-based LTZ Therapeutics has reportedly raised USD 40 million in a Series A+ financing round led by Wanwu Growth Venture Capital. The round also saw participation from Lanchi Ventures, 5Y Capital, Unicorn Capital Partners, the Institute for Follicular Lymphoma Innovation, and returning investors Lapam Capital and GL Ventures. The proceeds will be used to advance the Phase I clinical trial of its first drug candidate, LTZ-301, and to submit an Investigational New Drug (IND) application for its second candidate, LTZ-232, targeting pan-tumor indications.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32493#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32493\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32493#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2705.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2705.webp\",\"width\":1080,\"height\":608,\"caption\":\"LTZ Therapeutics Secures $40M Series A+ to Advance Immunotherapy Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32493#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LTZ Therapeutics Secures $40M Series A+ to Advance Immunotherapy Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"LTZ Therapeutics Secures $40M Series A+ to Advance Immunotherapy Pipeline - Insight, China's Pharmaceutical Industry","description":"Shenzhen-based LTZ Therapeutics has reportedly raised USD 40 million in a Series A+ financing round led by Wanwu Growth Venture Capital. The round also saw participation from Lanchi Ventures, 5Y Capital, Unicorn Capital Partners, the Institute for Follicular Lymphoma Innovation, and returning investors Lapam Capital and GL Ventures. The proceeds will be used to advance the Phase I clinical trial of its first drug candidate, LTZ-301, and to submit an Investigational New Drug (IND) application for its second candidate, LTZ-232, targeting pan-tumor indications.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32493","og_locale":"en_US","og_type":"article","og_title":"LTZ Therapeutics Secures $40M Series A+ to Advance Immunotherapy Pipeline","og_description":"Shenzhen-based LTZ Therapeutics has reportedly raised USD 40 million in a Series A+ financing round led by Wanwu Growth Venture Capital. The round also saw participation from Lanchi Ventures, 5Y Capital, Unicorn Capital Partners, the Institute for Follicular Lymphoma Innovation, and returning investors Lapam Capital and GL Ventures. The proceeds will be used to advance the Phase I clinical trial of its first drug candidate, LTZ-301, and to submit an Investigational New Drug (IND) application for its second candidate, LTZ-232, targeting pan-tumor indications.","og_url":"https:\/\/flcube.com\/?p=32493","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-27T08:43:41+00:00","article_modified_time":"2025-04-27T08:43:42+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2705.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32493#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32493"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"LTZ Therapeutics Secures $40M Series A+ to Advance Immunotherapy Pipeline","datePublished":"2025-04-27T08:43:41+00:00","dateModified":"2025-04-27T08:43:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32493"},"wordCount":163,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32493#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2705.webp","keywords":["Biotech","Finance","LTZ Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32493#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32493","url":"https:\/\/flcube.com\/?p=32493","name":"LTZ Therapeutics Secures $40M Series A+ to Advance Immunotherapy Pipeline - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32493#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32493#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2705.webp","datePublished":"2025-04-27T08:43:41+00:00","dateModified":"2025-04-27T08:43:42+00:00","description":"Shenzhen-based LTZ Therapeutics has reportedly raised USD 40 million in a Series A+ financing round led by Wanwu Growth Venture Capital. The round also saw participation from Lanchi Ventures, 5Y Capital, Unicorn Capital Partners, the Institute for Follicular Lymphoma Innovation, and returning investors Lapam Capital and GL Ventures. The proceeds will be used to advance the Phase I clinical trial of its first drug candidate, LTZ-301, and to submit an Investigational New Drug (IND) application for its second candidate, LTZ-232, targeting pan-tumor indications.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32493#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32493"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32493#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2705.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2705.webp","width":1080,"height":608,"caption":"LTZ Therapeutics Secures $40M Series A+ to Advance Immunotherapy Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32493#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"LTZ Therapeutics Secures $40M Series A+ to Advance Immunotherapy Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2705.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32493","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32493"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32493\/revisions"}],"predecessor-version":[{"id":32495,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32493\/revisions\/32495"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32494"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32493"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32493"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32493"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}